Nektar surges again as alopecia drug shows new promise in extension study
BioPharma Dive
Patients who'd seen substantial hair regrowth in the first part of Nektar s trial had a deepening treatment response, extending a comeback bid that s caused shares to skyrocket over the last year.
pharminent
April 20, 2026 (Last updated: April 20, 2026)
BioPharma Dive
Patients who’d seen substantial hair regrowth in the first part of Nektar s trial had a deepening treatment response, extending a comeback bid that s caused shares to skyrocket over the last year.
